Compare Ionis Pharmaceuticals Inc. Common Stock (IONS) vs IQVIA Holdings Inc. Common Stock (IQV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ionis Pharmaceuticals Inc. Common Stock vs IQVIA Holdings Inc. Common Stock — how do they compare? Ionis Pharmaceuticals Inc. Common Stock trades at $43.32 (market cap $7.10B), while IQVIA Holdings Inc. Common Stock trades at $264.98 (market cap $43.13B). The key difference: IQVIA Holdings Inc. Common Stock is far larger — about 6.1× Ionis Pharmaceuticals Inc. Common Stock's market cap, and IQVIA Holdings Inc. Common Stock is trading nearer its 52-week high, Ionis Pharmaceuticals Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ionis Pharmaceuticals Inc. Common Stock for 0 Days and IQVIA Holdings Inc. Common Stock for 6 Days on average.
| IONS | IQV | |
|---|---|---|
Market Cap | $7.10B | $43.13B |
Volume | 2,027,457 | 847,300 |
Sector | Health | Health |
52-Week High | $86.50 | $275.02 |
52-Week Low | $42.38 | $156.66 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $6.66B | $57.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IQVIA Holdings (IQV) trades at $260.71, down 0.57% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $284.64. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $3.15 surpassing the $3.03 estimate. Revenue growth is steady, projected at $17.0B for 2026, while profitability metrics like a 23.01% ROE and 8.1% net income margin reflect operational strength. The company continues to innovate, launching new predictive analytics tools for life sciences clients.
The outlook for IQV remains positive, supported by strong earnings performance and analyst optimism, though investors should note valuation multiples above sector averages and debt levels. Key risks include competitive pressures in clinical research services and macroeconomic sensitivity affecting client spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ionis Pharmaceuticals Inc. Common Stock
Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →About IQVIA Holdings Inc. Common Stock
IQVIA provides clinical research, healthcare data, technology, and consulting services to life sciences companies. Its work supports drug development and commercialization.
Read more on IQV →
